CRISPR screen for protein inclusion formation uncovers a role for SRRD in the regulation of intermediate filament dynamics and aggresome assembly.

"reviewer #1: no reviewer #2: no reviewer #3: no ---------------------------------------------------- data deposition if you have submitted a research article or front matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as genbank or arrayexpress) one way to make that data available is to deposit it in the dryad digital repository .; journalid=pgenetics&manu=pgenetics-d-23-00676r1 more information about depositing data in dryad is available at http://www datadryad org/depositing . file s1 table (xlsx"

"I have read the journal’s policy and the authors of this manuscript have the following competing interests: OS and KMS have filed a patent application for the use of SRRD fragments through the Children’s Hospital of Philadelphia. J.S. is a consultant for Dewpoint Therapeutics, ADRx, and Neumora. J.S. is a shareholder and advisor for Confluence Therapeutics. The authors declare no other conflicts of interest relevant to this publication."

"This work was supported by the following grants: NIH/NIGMS DP2GM137416 (OS, GC and ML, TL), PA DoH SAP#4100083086 (OS and SC, TL), NINDS/NIH R03NS111447-01 (OS), iAward Sanofi (OS), NINDS - F31NS116999 to KMS, The Packard Center (JS), TargetALS (JS), The Association for Frontotemporal Degeneration (JS), the Amyotrophic Lateral Sclerosis Association (JS), Office of the Assistant Secretary of Defense for Health Affairs through the Amyotrophic Lateral Sclerosis Research Program W81XWH-20-1-0242 and W81XWH-17-1-0237 (JS) G. Harold and Leila Y. Mathers Foundation (JS), NIH R01GM099836 (JS), NIH R21AG065854 (JS), EMB from (Milton Safenowitz Post-Doctoral Fellowship from the ALSA, NIH; BP from (AHA and the BrightFocus Foundation). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."